rIL-3

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NamerIL-3
Drug Alias NameHemokineSDZ-ILE-964rIL-3rhIL-3ILE-964
ClassificationBiologics > Protein drugs > Recombinant protein > Recombinant cytokines
Mechanisms of ActionInterleukin 3 receptor agonists
TargetsInterleukin 3 receptor
Therapy Area/IndicationsImmunologic Deficiency SyndromesPancytopeniaThrombocythemia, Essential +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusDiscontinued (Phase 3 Clinical)
Highest Status in ChinaN/A
Originator CompaniesPfizer Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesSandozPfizer Inc
Active IndicationsN/A
Inactive IndicationsImmunologic Deficiency SyndromesPancytopeniaThrombocythemia, Essential +[5] 

Other Information

ATC CodeN/A
Related LinksN/A